Sammanfattning
Mutations in the Lamin A/C gene (LMNA) are a new part of the spectrum of genes responsible for sudden cardiac death (SCD). Relatives of SCD-cases should receive counselling, clinical assessment and perhaps molecular screening. The consequence of being an LMNA mutation carrier is discussed with regard to counselling and prophylactic measures. Device therapy may be relevant in LMNA-mutation carriers, although the proper time for implantation is uncertain. However, we recommend LMNA genetic screening in SCD cases with dilated cardiomyopathy as well as cases with unexplained SCD.